{"organizations": [], "uuid": "253704e3de3a4b02110a2d074fcfeb56838807e2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/futures", "section_title": "Futures - Markets | Reuters.com", "url": "https://www.reuters.com/article/brief-sage-therapeutics-receives-fda-bre/brief-sage-therapeutics-receives-fda-breakthrough-therapy-designation-for-sage-217-idUSASB0C4EY", "country": "US", "domain_rank": 408, "title": "BRIEF-Sage Therapeutics Receives FDA Breakthrough Therapy Designation For Sage-217", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.909, "site_type": "news", "published": "2018-02-07T19:39:00.000+02:00", "replies_count": 0, "uuid": "253704e3de3a4b02110a2d074fcfeb56838807e2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sage-therapeutics-receives-fda-bre/brief-sage-therapeutics-receives-fda-breakthrough-therapy-designation-for-sage-217-idUSASB0C4EY", "ord_in_thread": 0, "title": "BRIEF-Sage Therapeutics Receives FDA Breakthrough Therapy Designation For Sage-217", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "sage therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 7 (Reuters) - Sage Therapeutics Inc:\n* SAGE THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR SAGE-217 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER\n* SAGE THERAPEUTICS INC - SAGE-217 WAS GENERALLY WELL-TOLERATED\n* SAGE THERAPEUTICS INC - IN TRIAL, SAGE-217 MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-07T19:39:00.000+02:00", "crawled": "2018-02-07T13:46:57.000+02:00", "highlightTitle": ""}